Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application by Sadremomtaz, Afsaneh et al.
 
 
 University of Groningen
Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor
(VEGF) B based peptide as antiangiogenic agent targeting the second domain of the
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application
Sadremomtaz, Afsaneh; Ali, Ameena M; Jouyandeh, Foroozan; Balalaie, Saeed; Navari,
Razieh; Broussy, Sylvain; Mansouri, Kamran; Groves, Matthew R; Asghari, S Mohsen
Published in:
Signal transduction and targeted therapy
DOI:
10.1038/s41392-020-0177-z
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Sadremomtaz, A., Ali, A. M., Jouyandeh, F., Balalaie, S., Navari, R., Broussy, S., Mansouri, K., Groves, M.
R., & Asghari, S. M. (2020). Molecular docking, synthesis and biological evaluation of Vascular Endothelial
Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application. Signal
transduction and targeted therapy, 5(1), [76]. https://doi.org/10.1038/s41392-020-0177-z
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
LETTER OPEN
Molecular docking, synthesis and biological evaluation of
Vascular Endothelial Growth Factor (VEGF) B based peptide
as antiangiogenic agent targeting the second domain of the
Vascular Endothelial Growth Factor Receptor 1
(VEGFR1D2) for anticancer application
Signal Transduction and Targeted Therapy            (2020) 5:76 ; https://doi.org/10.1038/s41392-020-0177-z
Dear Editor,
Tumor angiogenesis is regulated by the binding of VEGF to
receptors (VEGFRs). The major mediator of tumor angiogenesis is
VEGFA, more commonly referred to as VEGF. VEGFR1 binds VEGF
with higher affinity (10 times) than VEGFR2.1 However, the role of
the VEGFR1 in VEGF-mediated angiogenesis remains a mystery.
In order to disrupt the VEGFB–VEGFA/VEGFR1D2 interaction as a
tool to study the angiogenesis process,1,2 the first step was the
generation of a second extracellular domain of the VEGFR1.
Hence, His-tagged VEGFR1D2 was expressed and purified
(Supplementary Fig. S1). The addressed protein could be used in
biophysical, biological, and in vivo studies with an appropriate
VEGF receptor binding peptide. Such a peptide could be designed
and synthesized (Supplementary Figs. S1–S6) and (Supplementary
Tables S1 and S2).
The aim of this study was to develop a simplified system to
enable the rational design of inhibitor of VEGFB–VEGFA/
VEGFR1D2 system (PDB ID:2XAC and 1FLT). Among large surface
areas comprising five main interacting regions, a small peptide
antagonist could be designed and only act at a single site
covering a small surface area with high-affinity interaction. Here,
we described designing such a peptide referred to as VGB3 using
“protein contact atlas”, “LigPlot” and “PocketQuery”. VGB3 binds
and neutralizes VEGFR1D2. A major binding site for VEGFR1D2
binding involves residues 60–67 (the loop region connecting β3 to
β4), 62-PDDGL-66, and strand β7 (103–106) 102-ECRP-105 of
VEGFB.1,3 In addition, to increase peptide half-life in circulation, a
Cys residue was added to the C terminus to make the disulfide
bond. The loop region has more numbers of acidic residues, which
are highlighted by LigPlot and PocketQuery, and could be
recognized as polar interactions with VEGFR1D2. In good
agreement, Iyer et al. reported the similarity of interactions in all
three receptor bound complexes of VEGFB–VEGFR1D2,
VEGFA–VEGFR1D2, and PlGF–VEGFR1D2 by this acidic stretch of
residues. It would be assumed that these polar interactions would
play an important role in VEGFB:VEGFR1D2 complex.1 Next, the
peptide was designed and synthesized by using a solid-phase
peptide synthesis procedure. Accordingly, the mimetic decapep-
tide VGB3 introduced by this sequence; 2NH-Glu1-Cys2-Arg3-
Pro4-Pro5-Asp6-Asp7-Gly8-Leu9-Cys10-COOH.
To gain structural information about the molecular interface of
the bound VGB3 peptide, a structural model of VGB3/VEGFR1D2
complex has been generated using the ZDOCK web server. The
binding energetic of VGB3/VEGFR1D2 was calculated and the free
binding of energy value is −30.819 kcal/mol. The energetic
analysis also supported this finding, that is, VGB3 can bind tightly
to VEGFR1D2 as compared with free energy of binding for same
antagonist target complexes.1,3 Analysis of the VGB3:VEGFR1D2
interface Ligplot+ and Pocketquery shows direct interactions
between VGB3 and residues within the loop region connecting β3
to β4 and strand β7 of VEGFR1D2 (Fig. 1b). In the VGB3:VEGFR1D2
complex, the residues from this loop region make a total of 14 van
der waals interactions with Pro143, Leu204, Phe172, Lys170,
Pro173, Leu174, Lys171, Thr206, Glu208, Leu215, and Lys217 of
VEGFR-1D2.3,4 The most van der Waals contacts were from
hydrophobic residues such as Phe172 and Leu204 of VEGFR1D2
to Cys2, Arg3, Cys10, and Leu9 of VGB3. In order to highlight the
crucial role of polar interaction in the loop region, Iyer et al.
performed the mutation and the results indicated 67% of total
interactions of VEGFB (a total of 12 interactions). Detailed
comparison of full crystal structure VEGFB:VEGFR1D2 complex
(PDB: 2XAC) and present derivative VGB3:VEGFR1D2 complex
gives an insight as to why this might be the case. All active
residues in interaction VGB3 to VEGFR1D2 are listed in Table S3,
which includes mostly a network of van der Waals and polar
contacts (Fig. 1a and Supplementary Table S3). Potential polar
contacts can also be identified involving amide groups of the
VEGFR1D2 surface and carboxyl group of side chains of the
peptide.
Subsequently, to verify the ability of VGB3 to form a complex
with VEGFR1D2, microscale thermophoresis (MST) measurements
were performed using a VEGFR1D2-labeled with VGB3 at
increasing concentrations. As well as measuring the Kd between
VGB3 and its receptor this functional test will also confirm whether
the refolded protein VEGFR1D2 assumes the correct conformation.
Fluorescently labeled VEGFR1D2 purified and titrated as 1:1 with
VGB3. The curve for VGB3 vs VEGFR1D2 exhibited a dissociation
constant (Kd) of 1.96 ± 0.69 μM (Fig. 1b). It should be noted that
this binding constant is 40-fold lower than the Kd (Kd= ~50 nM) of
VEGFA to the entire extracellular portion of VEGFR1. Previously, a
tight association between VEGFR1 D2 and VEGF has also been
reported (113pM).4 This difference between VGB3 and VEGF in
affinity indicates that multiple regions of VEGF are required in the
binding of VEGFR. However, the single digit micro molar affinity
measured in MST indicates that the dominant portion of the
binding interaction is mimicked by the VGB3 peptide.
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Moreover, VEGFR1 binding property of VGB3 was confirmed by
its ability to inhibit the proliferation of 4T1 mammary carcinoma
cell line, which highly express VEGFR1.1,2,5 VGB3 could inhibit
VEGF165 (0.75 pM)-stimulated proliferation of 4T1 mammary
carcinoma cells, which express VEGFR1, with the half maximal cell
growth inhibitory concentration (IC50) of 30 nM (****P < 0.0001)
(Fig. 1c and Supplementary Fig. S7). This value is 6-fold lower than
the one for the VEGFR1D2 fragments those which can inhibit
VEGF165-stimulated proliferation of human umbilical vein
endothelial cells with an IC50 of ~180 nM.3 These results suggest
that VGB3 is more potent than other peptides reported by those
which have been designed from the same ligand.2,4,5 Similarly, in
other investigations, the VEGFR-1-binding ELISA-based assay
developed and allows us to approve the inhibitory effect VGB3
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on the VEGF-A/VEGFR-1 interaction. VGB3 had significantly
increased potency, up to 63% displacement of btVEGF165 (100
pM) detected at 100 μM as compared to the potential antiproli-
ferative potency of VGB3 to inhibit 50% VEGFA (0.75 pM)-induced
proliferation of the HUVEC as well as 4T1 mammary carcinoma cell
lines at 30 nM (Fig. 1c–e and Supplementary Fig. S7). By
comparison, VGB3, with an IC50 value of 30 nM, more effectively
inhibited endothelial cell proliferation than other peptides that we
recently reported based on the binding regions of VEGF-B.2,4,5 In
good agreement, our study showed that VGB3 is more potent
than those of clinically used antiangiogenic cancer drugs such as
Bevacizumab in endothelial cell culture conditions.2,4,5
The antitumor effects of VGB3 were examined in the murine 4T1
mammary carcinoma tumor model (MCT), which is a well-
established VEGFR1-dependent model.2,5 Following intravenous
administration, the in vivo tumor regression was performed and
the inhibitory effects of VGB3 on tumor growth and angiogenesis
were definitely higher (0.2 mg/kg, once in every 2 days) than those
which have reported by same background antiangiogenic drugs
such as bevacizumab (2 mg/kg, twice per week) (Fig. 1f). In good
agreement with immunohistochemistry analysis (as evidenced by
decreased CD31, CD34, Ki67 expression, Bcl-2 and increased
TUNEL staining and p53 expression), suggest that the antitumor
efficacy of VGB3 is closely correlated with its antiangiogenic effect
and with the induction of apoptosis in a xenograft mouse model.
On the basis of these results, VGB3, through neutralization of
VEGFR-1, that could be indirectly involved in impairing many
angiogenesis signaling pathways, which lied at downstream of
VEGFR1 (Fig. 1g).
Our results confirm that targeting VEGFR1 is a reliable approach
for inhibition of tumor growth and angiogenesis and VGB3 can be
a candidate for antiangiogenic therapy.
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Fig. 1 a Docking studies. The derived molecular model was created using ZDOCK. The models were created by PEPFOLD3 software, version
9.16, and figures were generated with a UCSF Chimera. Ligplot+ & Pocketquery generated representation of the interaction between VGB3
and VEGFR1D2. The polar and van der Waals interactions are indicated in green and orange, respectively. The Pocketquery results identify side
chains of VGB3 residues that may be involved in important interactions (Polar and van der Waals interactions) at the complex interface, as
listed in Table S3. b MST curve. The result of binding of VGB3 to VEGFR1D2 at a stoichiometry of 1:1. The assay was performed using a fixed
concentration of fluorescently labeled VEGFR1D2 and the initial concentration of ligand was 0.25 mM. c The effect of VGB3 on VEGF-
stimulated cell proliferation. The effect of VGB3 on cell proliferation was determined on endothelial cells as well as 4T1 tumor cells. The cells
with (dark grey) and without VEGF (light grey) were treated with various concentration ranges (0–0.061 μM) of VGB3 and then an MTT assay
was performed to measure cell viability at two time points (24 and 48 h). Data points are mean ± SEM, obtained by Prism 6. Unpaired two-
tailed t-test (to compare the differences between No-VEGF and VEGF in each concentration) and one-way ANOVA with Tukey multiple
comparison; n= 6, NS no significant. d ELISA-based displacement assay. Bars represent mean ± SEM, obtained by Prism 6; one-way ANOVA
with Tukey multiple comparison. e VGB3 inhibits angiogenesis in vitro. VGB3 inhibits migration of wounded HUVEC monolayers compared
with the control. VGB3 decoy assessment in HUVEC Cytodex 3D bead sprouting assay which followed by embedding into the collagen gel in
the presence of VEGF (0.75 pM) as stimulator following exposure to increasing concentrations of VGB3. Analytical results of mean data are
shown for each concentrations. Bars represent mean ± SEM, obtained by Prism 6. Unpaired two-tailed t-test and one-way ANOVA with Tukey
multiple comparison, NS no significant. f VGB3 inhibits 4T1 metastatic breast cancer growth in vivo. Significant inhibition of tumor growth
occurred in animals treated with VGB3 when compared with control. Data points are mean ± SEM, obtained by Prism 6 in two-way ANOVA
statistical analysis; n= 6. The differences between VGB3 treatments and PBS controls are demonstrated; *P ≤ 0.05 (0.02 mg/kg of VGB3 to PBS
control), ***P ≤ 0.001 (0.2 mg/kg of VGB3 to PBS control), no significant (0.1 mg/kg and 0.5 mg/kg of VGB3 to PBS control). The average body
weight of each group was measured until the size of the tumor in the control animals reached the endpoint of the study (from day 13 till 31),
then presented as mean ± SEM. The data indicated no significant (NS) differences between VGB3 treatments and PBS controls in two-way
ANOVA statistical analysis. g Mechanistic basis for VGB3-mediated tumor inhibition in vivo. Data were analyzed by ImageJ, and visualized as
columns bars using Prism 6. Results shown are representative or mean ± SEM (n= 6). The differences between VGB3 treatments (0.2 mg/kg)
and PBS controls were assessed by unpaired two-tailed t-test
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Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
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